返回 
加入收藏
膦甲酸钠联合重组人干扰素α2b治疗宫颈HPV持续感染的疗效观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 膦甲酸钠联合重组人干扰素α2b治疗宫颈HPV持续感染的疗效观察 |
| TITLE： | |
| 摘要： | 目的：观察膦甲酸钠联合重组人干扰素α2b治疗宫颈人乳头瘤病毒（HPV）持续感染的临床疗效。方法：选取宫颈HPV持续感染患者65例，按照随机数字表法分为治疗组（n＝35）和对照组（n＝30）。两组患者均给予重组人干扰素α2b栓10万IU，qod（睡前），治疗时间为3个月；治疗组患者在此基础上给予膦甲酸钠氯化钠注射液250 mL，ivgtt，qd，治疗时间为14 d。观察两组患者根据HPV病毒载量判定的疗效、HPV转阴率、宫颈炎评分、根据宫颈炎评分改善率判定的疗效及不良反应发生情况。结果：治疗组患者根据HPV病毒载量判定的总有效率（94.29％）明显高于对照组（76.67％），差异有统计学意义（P＜0.05）；治疗组患者HPV转阴率（77.14％）明显高于对照组（36.67％），差异有统计学意义（P＜0.05）。两组患者宫颈炎评分均较治疗前明显降低，且治疗组[（1.49±0.70）分]明显低于对照组[（1.97±0.89）分]，差异均有统计学意义（P＜0.05）；治疗组患者根据宫颈炎评分改善率判定的总有效率（88.57％）明显高于对照组（73.33％），差异有统计学意义（P＜0.05）。两组患者治疗过程中均未见不良反应发生。结论：膦甲酸钠联合重组人干扰素α2b能有效抑制HPV病毒复制、提高HPV转阴率、缓解宫颈炎症状，且安全性较高。 |
| ABSTRACT： | OBJECTIVE： To observe the clinical efficacy of foscarnet sodium combined with recombinant human interferon α2b in the treatment of persistent infection of cervical HPV. METHODS： A total of 65 patients infected with HPV were enrolled in the study and divided into treatment group （n＝35） and control group （n＝30）. Both groups were treated with recombinant human interferon α2b 100 000 IU， qod （at bedtime）， for 3 months； treatment group was additionally treated with Foscarnet chloride and sodium chloride injection 250 mL， ivgtt， qd， for 14 d. Therapeutic efficacy based on HPV viral loading amount， negative rate of HPV and cervicitis score were observed in 2 groups as well as therapeutic efficacy based on cervicitis score improvement rate and the occurrence of ADR. RESULTS： Total effective rate based on HPV viral loading amount of treatment group （94.29％） was significantly higher than that of control group （76.67％）， with statistical significance （P＜0.05）. The negative rate of HPV in treatment group （77.14％） was significantly higher than in control group （36.67％）， with statistical significance （P＜0.05）.The cervicitis scores of 2 groups were decreased significantly compared to before treatment， the treatment group [（1.49±0.70）score] was significantly lower than the control group [（1.97±0.89）score]， with statistical significance （P＜0.05）. The total effective rate based on improvement rate of cervicitis scores of treatment groups （88.57％） was significantly higher than that of control group （73.33％）， with statistical significance （P＜0.05）. No ADR was found in 2 groups during treatment. CONCLUSIONS： Foscarnet sodium combined with recombinant human interferon α2b can effectively inhibit HPV virus， improve the negative rate of HPV， and also relieve the cervicitis with good safety. |
| 期刊： | 2017年第28卷第2期 |
| 作者： | 董丽花，徐永萍，范明华 |
| AUTHORS： | DONG Lihua，XU Yongping，FAN Minghua |
| 关键字： | 膦甲酸钠；重组人干扰素α2b；宫颈；人乳头瘤病毒；持续感染 |
| KEYWORDS： | Foscarnet sodium； Recombinant human interferon α2b；Cervical； Human papillomavirus；Persistent infection |
| 阅读数： | 501 次 |
| 本月下载数： | 4 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
